Evidence map›Paper›PMID 41743344›Full record

ArticleGlobal health & medicine2026

Prognostic comparison between osteoblastic and osteolytic metastases in prostate cancer.

Akihiro Ono, Kazuki Akiyama, Ryohei Nishimoto, Ryo Amakawa, Yasushi Inoue, Tadashi Yoshimatsu, Yoshiyuki Shiga, Masashi Kusakabe, Haruyasu Yamada, Satoru Taguchi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Global health & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Akihiro OnoDepartment of Urology, NTT Medical Center Tokyo, Tokyo, Japan.
Kazuki AkiyamaDepartment of Urology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan.
Ryohei NishimotoDepartment of Urology, NTT Medical Center Tokyo, Tokyo, Japan.
Ryo AmakawaDepartment of Urology, NTT Medical Center Tokyo, Tokyo, Japan.
Yasushi InoueDepartment of Urology, NTT Medical Center Tokyo, Tokyo, Japan.
Tadashi YoshimatsuDepartment of Urology, NTT Medical Center Tokyo, Tokyo, Japan.
Yoshiyuki ShigaDepartment of Urology, NTT Medical Center Tokyo, Tokyo, Japan.
Masashi KusakabeDepartment of Radiology, NTT Medical Center Tokyo, Tokyo, Japan.
Haruyasu YamadaDepartment of Radiology, NTT Medical Center Tokyo, Tokyo, Japan.
Satoru TaguchiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Haruki KumeDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Masaki NakamuraDepartment of Urology, NTT Medical Center Tokyo, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over 80% of patients develop bone metastases in the advanced stages of prostate cancer, resulting in a poor prognosis. To date, no study has explored the relationship between the type of bone metastasis and patient outcomes. The objective of this study was to compare the clinical features and prognoses of patients with osteoblastic and osteolytic bone metastases. Among the 63 patients diagnosed with bone metastases from prostate cancer at our institution between May 2011 and September 2023, 51 were classified as having osteoblastic metastases and 12 as having osteolytic metastases based on imaging findings. Overall survival was analyzed using Kaplan-Meier survival curves, and differences between groups were assessed using the log-rank test. Clinical parameters were compared using the Mann-Whitney

Indexed as

bone metastasesosteoblasticosteolyticprostate cancer

Identifiers

PMID41743344
PMCPMC12932056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.